Objective To evaluate the long-term efficacy and safety of Ultrasound (US)-guided percutaneous thermal ablation for recurrent or persistent secondary hyperparathyroidism (SHPT) and identify predictors of treatment failure. Materials and methods From January 2014 to July 2023, 102 patients with recurrent or persistent SHPT after parathyroidectomy or ablation received thermal ablation. The median follow-up period was 30 months. The primary endpoint was the proportion of participants who achieved target parathyroid hormone (PTH) levels (≤ 300 pg/mL) at the end of follow-up. The secondary endpoints were the mean changes in levels of PTH, calcium, phosphorus, and alkaline phosphatase (ALP) from baseline; the technical success rate; and complications. Univariate and multivariate logistic regression analyses were performed to identify independent prognostic factors affecting the prognosis of ablation. Results A total of 102 participants (mean age, 52 ± 12 years) with 174 hyperplastic parathyroid glands were evaluated. Overall, 87.3% of the participants achieved the target PTH level. Compared to baseline, significant reduction was achieved in PTH, calcium, phosphorus, and ALP levels (p < 0.05). The technical success rate was 100%. For major complications, one (1.0%) participant experienced persistent laryngeal nerve paralysis after ablation, and severe hypocalcemia occurred in 29 participants but did not result in serious comorbidities following calcium supplementation. The only independent predictor of treatment failure was baseline PTH ≥ 1606 pg/mL (odds ratio, 5.1; 95% CI: 1.1–23.1; p = 0.04). Conclusions US-guided thermal ablation is safe and effective for recurrent or persistent SHPT. Baseline PTH ≥ 1606 pg/mL is a key predictor of treatment failure. Key Points <Emphasis Type="BoldItalic">Question</Emphasis> Recurrent/persistent SHPT lacks safe, minimally invasive therapies, while traditional repeat surgery poses high complication risks due to fibrosis and anatomical distortion. <Emphasis Type="BoldItalic">Findings</Emphasis> The study demonstrated 87.3% in achieving target PTH levels. The incidence of severe hypocalcemia reached 28.4%. <Emphasis Type="BoldItalic">Clinical relevance</Emphasis> This pioneering multicenter study with a large sample size demonstrates the long-term effectiveness and safety of US-guided percutaneous thermal ablation for treating recurrent and persistent SHPT. It offers a viable nonsurgical alternative for managing this condition. Graphical Abstract

Efficacy and safety of thermal ablation for the treatment of recurrent and persistent secondary hyperparathyroidism: a multicenter retrospective study

期刊论文
发表日期：

2025年8月6日

查看全文

Yang Liu,
Songsong Wu,
Chengzhong Peng,
Huihui Chai,
Mingan Yu,
Linxue Qian,
Yue Shan,
Luxin Zhang,
Jie Yu,
Fangyi Liu,
Ping Liang

摘要

Objective

To evaluate the long-term efficacy and safety of Ultrasound (US)-guided percutaneous thermal ablation for recurrent or persistent secondary hyperparathyroidism (SHPT) and identify predictors of treatment failure.

Materials and methods

From January 2014 to July 2023, 102 patients with recurrent or persistent SHPT after parathyroidectomy or ablation received thermal ablation. The median follow-up period was 30 months. The primary endpoint was the proportion of participants who achieved target parathyroid hormone (PTH) levels (≤ 300 pg/mL) at the end of follow-up. The secondary endpoints were the mean changes in levels of PTH, calcium, phosphorus, and alkaline phosphatase (ALP) from baseline; the technical success rate; and complications. Univariate and multivariate logistic regression analyses were performed to identify independent prognostic factors affecting the prognosis of ablation.

Results

A total of 102 participants (mean age, 52 ± 12 years) with 174 hyperplastic parathyroid glands were evaluated. Overall, 87.3% of the participants achieved the target PTH level. Compared to baseline, significant reduction was achieved in PTH, calcium, phosphorus, and ALP levels (p < 0.05). The technical success rate was 100%. For major complications, one (1.0%) participant experienced persistent laryngeal nerve paralysis after ablation, and severe hypocalcemia occurred in 29 participants but did not result in serious comorbidities following calcium supplementation. The only independent predictor of treatment failure was baseline PTH ≥ 1606 pg/mL (odds ratio, 5.1; 95% CI: 1.1–23.1; p = 0.04).

Conclusions

US-guided thermal ablation is safe and effective for recurrent or persistent SHPT. Baseline PTH ≥ 1606 pg/mL is a key predictor of treatment failure.

Key Points

Question Recurrent/persistent SHPT lacks safe, minimally invasive therapies, while traditional repeat surgery poses high complication risks due to fibrosis and anatomical distortion.

Findings The study demonstrated 87.3% in achieving target PTH levels. The incidence of severe hypocalcemia reached 28.4%.

Clinical relevance This pioneering multicenter study with a large sample size demonstrates the long-term effectiveness and safety of US-guided percutaneous thermal ablation for treating recurrent and persistent SHPT. It offers a viable nonsurgical alternative for managing this condition.

Graphical Abstract